Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 4:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nonmalignant Condition Clear all
Suspended No phase listed Observational

Narrow Band Imaging Project on Barrett's Esophagus

NCT01580631
View directory record Official record
Conditions
Barrett's Esophagus, Gastroesophageal Reflux Disease
Interventions
Not listed
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Sep 7, 2026, 4:33 AM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases

NCT02277639
View directory record Official record
Conditions
Bone Marrow Failure Syndromes, Immunodeficiencies, Immune Dysregulation Syndromes
Interventions
CliniMACs device
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 22 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Sep 7, 2026, 4:33 AM EDT
Completed Not applicable Interventional

Indoor Daylight Photo Dynamic Therapy for Actinic Keratosis

NCT03805737
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Amulez and sunlight, Amulez and red light treatment
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Sep 7, 2026, 4:33 AM EDT
Completed Phase 3 Interventional Results available

Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids

NCT01192295
View directory record Official record
Conditions
Pain
Interventions
Oxycodone HCl controlled-release tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
6 Years to 16 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 7, 2026, 4:33 AM EDT
Recruiting No phase listed Observational

Endometrial Cancer Vaginal Fluid Specimen Collection Study

NCT07544680
View directory record Official record
Conditions
Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia, Endometrial Intraepithelial Neoplasia
Interventions
Not listed
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
4,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Sarasota, Florida • Scarborough, Maine • Murfreesboro, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 7, 2026, 4:33 AM EDT
Recruiting Phase 2 Interventional

TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

NCT04356469
View directory record Official record
Conditions
Hemoglobinopathy (Disorder), Severe Aplastic Anemia, Bone Marrow Failure Syndrome
Interventions
Haploidentical Hematopoietic Cell Transplantation
Biological
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
0 Years to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 7, 2026, 4:33 AM EDT
Completed Not applicable Interventional

A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses

NCT01502020
View directory record Official record
Conditions
Actinic Keratoses
Interventions
imiquimod cream, 3.75%, Vehicle Cream
Drug
Lead sponsor
Actavis Mid-Atlantic LLC
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Birmingham, Alabama • Miami, Florida • Newnan, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Sep 7, 2026, 4:33 AM EDT
Completed Not applicable Interventional Results available

Patient Acceptance and Preference Among Screening Modalities for Detection of Barrett's Esophagus

NCT04301986
View directory record Official record
Conditions
Barrett Esophagus, GERD
Interventions
Cytosponge, Transnasal Endoscopy (TNE), Esophagogastroduodenoscopy
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2023 · Synced Sep 7, 2026, 4:33 AM EDT
Not listed Phase 2 Interventional

Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx

NCT00002454
View directory record Official record
Conditions
Precancerous Condition
Interventions
autologous tumor cell vaccine
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
1 Year and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1971
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Sep 7, 2026, 4:33 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

NCT03285477
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Placebo, KX2-391 Ointment 1%
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Mobile, Alabama • Glendale, Arizona • Fremont, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 7, 2026, 4:33 AM EDT
Not listed Phase 2 Interventional

Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma

NCT02018367
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Proflavine, high resolution imaging
Drug
Lead sponsor
Anandasabapathy, Sharmila, M.D.
Individual
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Sep 7, 2026, 4:33 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC

NCT04295811
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
Interventions
EsoGuard (lab assay), Esophagogastroduodenoscopy
Device · Diagnostic Test
Lead sponsor
Lucid Diagnostics, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
470 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
32
States / cities
Birmingham, Alabama • Orange, California • Aurora, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced Sep 7, 2026, 4:33 AM EDT
Completed Phase 2 Interventional Results available

Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus

NCT01298999
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
YF476, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 7, 2026, 4:33 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

NCT03236428
View directory record Official record
Conditions
Monoclonal Gammopathy, Smoldering Multiple Myeloma
Interventions
Daratumumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
6
States / cities
Monterey, California • Denver, Colorado • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 7, 2026, 4:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Survey Study on Barrett's Esophagus Screening

NCT04408105
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Barrett's Esophagus, Esophagus Adenocarcinoma
Interventions
Primary Care Provider Survey, Gastroenterologist Survey, Patient Survey
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
725 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
7
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 7, 2026, 4:33 AM EDT
Active, not recruiting Phase 2 Interventional

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

NCT05014646
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Cholestyramine, Leflunomide
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Duarte, California • Detroit, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 7, 2026, 4:33 AM EDT
Enrolling by invitation No phase listed Observational

The Johns Hopkins Heartburn Center Registry

NCT03853772
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Barrett Esophagus, Laryngopharyngeal Reflux, Esophagitis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
9
States / cities
Orange, California • Baltimore, Maryland • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 7, 2026, 4:33 AM EDT
Completed Phase 1 Interventional

EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer

NCT00004258
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cilengitide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Sep 7, 2026, 4:33 AM EDT
Withdrawn Phase 2 Interventional

A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia

NCT01925378
View directory record Official record
Conditions
Cervical Dysplasia
Interventions
Nelfinavir
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 7, 2026, 4:33 AM EDT
Completed Phase 2Phase 3 Interventional

Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

NCT01019876
View directory record Official record
Conditions
Bone Marrow Failure, Osteopetrosis, Fanconi Anemia, Severe Combined Immunodeficiency
Interventions
Fludarabine, Cyclophosphamide, Busulfan, Alemtuzumab, Rabbit Anti-thymocyte Globulin, Horse Anti-thymocyte Globulin
Drug
Lead sponsor
Columbia University
Other
Eligibility
Up to 30 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 7, 2026, 4:33 AM EDT
Terminated Phase 2 Interventional Results available

Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma

NCT00942422
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Interventions
defined green tea catechin extract, gene expression analysis, protein analysis, laboratory biomarker analysis
Dietary Supplement · Genetic · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Sep 7, 2026, 4:33 AM EDT
Completed Phase 3 Interventional Results available

Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp

NCT00304239
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Metvix-PDT, Vehicle-PDT
Combination Product
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Naperville, Illinois • Louisville, Kentucky • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 7, 2026, 4:33 AM EDT
Completed No phase listed Observational

Natural History of Oro-pharyngeal Cancer Precursors

NCT00179361
View directory record Official record
Conditions
Precancerous Conditions, Leukoplakia, Erythroplasia, Oral Papillomas
Interventions
Not listed
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Sep 7, 2026, 4:33 AM EDT
Not yet recruiting Phase 2 Interventional

Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases

NCT07660783
View directory record Official record
Conditions
Bone Marrow Failure, Hemoglobinopathies, Primary Immune Deficiency (PID), Autoimmune Cytopenia, Immune Dysregulation, Hemophagocytic Lymphohistiocytosis (HLH), Non Malignant Disorders
Interventions
ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 7, 2026, 4:33 AM EDT